The Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances In Vitro Maintenance and Proliferation of Human CD34+CD38−/low Cells Capable of Repopulating Severe Combined Immunodeficiency Mice
Open Access
- 1 August 1999
- journal article
- Published by American Society of Hematology in Blood
- Vol. 94 (3) , 923-931
- https://doi.org/10.1182/blood.v94.3.923.415k08_923_931
Abstract
In vitro maintenance and proliferation of human hematopoietic stem cells is crucial for many clinical applications. Early hematopoietic cells express low levels of FLT-3 and c-kit receptors, as well as the interleukin-6 (IL-6) receptor signal transducing element, gp130, but do not express IL-6 receptor itself. Therefore, we have attempted to maintain human cord blood or bone marrow CD34+ cells ex vivo in serum-free cultures containing stem cell factor (SCF) and FLT-3 ligand (FL) alone or together with a new recombinant molecule of soluble IL-6 receptor fused to IL-6 (IL6RIL6 chimera). The effect of IL6RIL6 chimera on the proliferation and differentiation of CD34+ cells was compared with that of each chimera component added separately. The engraftment potential of in vitro-cultured cells was determined using our recently established functional in vivo assay for primitive human severe combined immunodeficiency (SCID)-repopulating cells (SRC). We report here that IL6RIL6 chimera induced significantly higher levels of progenitors and SRC compared with SCF + FL alone or together with IL-6 and soluble IL-6 receptor. IL6RIL6 chimera prolonged in vitro maintenance of SRC for up to 14 days. Stimulation of CD34+CD38−/low enriched cells with IL6RIL6 chimera maintained the early CD34+CD38−/lowcell subpopulation, which could be detected in vitro for up to 14 days. Moreover, IL6RIL6 chimera preferentially stimulated the growth of early CD34+38−/low cells, resulting in significantly higher levels of progenitors compared with more mature CD34+38+ cells. Taken together, these findings demonstrate the importance of IL6RIL6 chimera in stimulating the proliferation of early CD34+· CD38−gp130+IL-6R−cells in vitro and extended maintenance of progenitors and SRC.Keywords
This publication has 42 references indexed in Scilit:
- Thrombopoietin, kit Ligand, and flk2/flt3 Ligand Together Induce Increased Numbers of Primitive Hematopoietic Progenitors From Human CD34+Thy-1+Lin− Cells With Preserved Ability to Engraft SCID-hu BoneBlood, 1998
- Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic– scid/scid miceProceedings of the National Academy of Sciences, 1997
- Quantitative Analysis Reveals Expansion of Human Hematopoietic Repopulating Cells After Short-term Ex Vivo CultureThe Journal of Experimental Medicine, 1997
- Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin.The Journal of Experimental Medicine, 1996
- Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.Proceedings of the National Academy of Sciences, 1996
- Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic systemImmunity, 1994
- Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiationBlood, 1993
- Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma.The Journal of Experimental Medicine, 1990
- The biology of interleukin-6Blood, 1989
- Host defense against infections and inflammations: Role of the multifunctional IL-6/IFN-β2 cytokineCellular and Molecular Life Sciences, 1989